Shirley Carrel

For smaller and mid-sized pharma companies, launch excellence isn’t just about bringing new molecules to market - it’s about maximizing the value of existing assets through reformulations, lifecycle extensions, and regional strategies. At Helsinn, Enrico Magnani has led global and regional launches in oncology and supportive care, where success is measured not just by speed to market, but by sustained value creation across the product lifecycle. Drawing on real-world experience, he’ll share how smaller companies can define success on their own terms and build agile, resource-smart strategies that deliver long-term impact. Attendees will leave with a practical framework for lifecycle-focused launch success beyond the first approval.

·       Launching reformulations with strategic intent and regional relevance

·       Defining success metrics that reflect company size and product type

·       Extending lifecycle value through agile, resource-smart planning